Publications

2026

A regulatory axis for tonotopic MYO7A expression in cochlear hair cells.

S. Li, S. Jun, Y. Kim, A. Gogineni, F. Lee, C.H. Kim, U. Kim, A.W. Peng, & J. Shin

PNAS, (2026) 123(15)

JCR IF: 9.1

Molecular remodeling of the central auditory pathway in tinnitus revealed by RNA sequencing.

H. H. Song, B. Lee, H. J. Shin, Y. R. Kim, S. Ham, U. K. Kim, I. Seo, D. J. Jung

Genes Genomics, (2026) 48(2): 317-325

JCR IF: 2.1

2025

DCTN1-associated neurological disorder with symptoms similar to spinal bulbar muscular atrophy.

B. Lee, S. T. Cho, R. Kim, K. W. Chung, T. J. Kwon, U. K. Kim, Y. R. Kim*, B. O. Choi* and J. S. Park*

J Neuromuscul Dis, (2025) 12(6): 804-813 (* These authors contributed equally to this work.)

JCR IF: 3.4

NGS-based identification of a MYO7A mutation in a Korean family with DFNB2, a subtype of autosomal recessive non-syndromic hearing loss.

Y. R. Kim*, B. Lee*, H. J Park, T. J. Kwon and U. K. Kim

Genes Genomics, (2025) 47(8): 891-897 (* These authors contributed equally to this work.)

JCR IF: 2.1

Inhibition of the mitochondrial permeability transition pore as a promising target for protecting auditory function in cisplatin-induced hearing loss.

Y. R. Kim*, S. Jun*, S. Jung, B. Lee, S. H. Lee, J. Lee, J. S. Hwang, T. Thoudam, H. Lee, I. S. Sinam, J. H. Jeon, K. Y. Lee, S. J. Min and U. K. Kim

Biomed Pharmacother (2025) 182:117767 (* These authors contributed equally to this work.)

JCR IF: 6.9

2024

Therapeutic effect of intraperitoneal dexamethasone on noise-induced permanent threshold shift in mice model.

B. Lee*, M. C. Kim*, Y. R. Kim*, J. H. Kim, T. J. Kwon, D. J. Jung, U. K. Kim and K. Y. Lee

Exp Brain Res (2024) 242(1): 257-265 (* These authors contributed equally to this work.)

JCR IF: 1.7

2023

Berberine chloride protects cochlear hair cells from aminoglycoside-induced ototoxicity by reducing the accumulation of mitochondrial reactive oxygen species.

Y. R. Kim*, J. I. Baek*, K. Y. Lee and U. K. Kim

Free Radic Biol and Med (2023) 204: 177-183 (* These authors contributed equally to this work.)

JCR IF: 7.1

Identification of an in-frame homozygous KIF1A variant causing a mild SPG30 phenotype in a Korean family.

B. Lee*, H. H. Song*, Y. R. Kim*, J. H. Kim, S. T. Cho, J. H. Lee, U. K. Kim and J. S. Park

Gene (2023) 870: 147403 (* These authors contributed equally to this work.)

JCR IF: 2.6

Mitochondrial redox system: A key target of antioxidant therapy to prevent acquired sensorineural hearing loss.

J. I. Baek*, Y. R. Kim*, K. Y. Lee and U. K. Kim

Front Pharmacol, (2023) 14: 1176881 (* These authors contributed equally to this work.)

JCR IF: 4.4

2022

Protective effect of berberine chloride against cisplatin-induced ototoxicity.

J. H. Kim, J. I. Baek, I. K. Lee, U. K. Kim, Y. R. Kim* and K. Y. Lee*

Genes Genomics, (2022) 44(1): 1-7 (* These authors contributed equally to this work.)

JCR IF: 2.1

2021

Microneedle array with a pH-responsive polymer coating and its application in smart drug delivery for wound healing.

A. Ullah, M. Jang, H. Khan, H. J. Choi, S. An, D. Kim, Y. R. Kim, U. K. Kim and G. M. Kim

Sensors and Actuators B-Chemical, (2021) 345

JCR IF: 9.22

Fursultiamine Prevents Drug-Induced Ototoxicity by Reducing Accumulation of Reactive Oxygen Species in Mouse Cochlea.

Y. R. Kim, T. J. Kwon, U. K. Kim, I. K. Lee, K. Y. Lee and J. I. Baek

Antioxidants, (2021) 10(10)

JCR IF: 7.68

2020

KL1333, a derivative of β-lapachone, protects against cisplatin-induced ototoxicity in mouse cochlear cultures.

H. S. Lee*, Y. R. Kim*, I. K. Lee, U. K. Kim, J. I. Beak, K. Y. Lee

Biomed Pharmacother, (2020) 126:110068 (* These authors contributed equally to this work.)

JCR IF: 6.53

2019

Gene therapy for hereditary hearing loss by SLC26A4 mutations in mice reveals distinct functional roles of pendrin in normal hearing.

M. A. Kim*, S. H. Kim*, N. Ryu, J. H. Ma, Y. R. Kim, J Jung, C. J. Hsu, J. Y. Choi, K. Y. Lee, P. Wangemann, J. Bok, and U. K. Kim

Theranostics, (2019) 23; 9(24): 7184-7199 (* These authors contributed equally to this work.)

JCR IF: 8.58

Modified U1 snRNA and antisense oligonucleotides rescue splice mutations in SLC26A4 that cause hereditary hearing loss.

B. Lee*, Y. R. Kim*, S. J. Kim*, S. H. Goh*, J. H. Kim, S. K. Oh, J. I. Baek, U. K. Kim and K. Y. Lee

Hum Mutat, (2019) (* These authors contributed equally to this work.)

JCR IF: 4.12

Targeted Gene Delivery into the Mammalian Inner Ear Using Synthetic Serotypes of Adeno-Associated Virus Vectors.

M. A. Kim, N. Ryu, H. M. Kim, Y. R. Kim, B. Lee, T. J. Kwon, J. Bok and U. K. Kim

Mol Ther Methods Clin Dev, (2019) 13, 197-204

JCR IF: 4.60

C-phycocyanin from Limnothrix Species KNUA002 Alleviates Cisplatin-Induced Ototoxicity by Blocking the Mitochondrial Apoptotic Pathway in Auditory Cells.

Y. R. Kim*, J. M. Do*, K. H. Kim*, A. R. Stoica, S. W. Jo, U. K. Kim and H. S. Yoon

Marine Drugs, (2019) 17(4) (* These authors contributed equally to this work.)

JCR IF: 4.07

CRISPR/Cas9-mediated genome editing of splicing mutation causing congenital hearing loss.

N. Ryu, M. A. Kim, D. G. Choi, Y. R. Kim, J. K. Sonn, K. Y. Lee and U. K. Kim

Gene, (2019) 703, 83-90

JCR IF: 2.98

Therapeutic potential of the mitochondria-targeted antioxidant MitoQ in mitochondrial-ROS induced sensorineural hearing loss caused by Idh2 deficiency.

Y. R. Kim*, J. I. Baek*, S. H. Kim*, M. A. Kim, B. Lee, N. Ryu, K. H. Kim, D. G. Choi, H. M. Kim, M. P. Murphy, G. Macpherson, Y. S. Choo, J. Bok, K. Y. Lee, J. W. Park and U. K. Kim

Redox Biology, (2019) 20, 544-555 (* These authors contributed equally to this work.)

JCR IF: 9.99